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Abstract
Background: Targeted mutagenesis of the herpesvirus genomes has been facilitated by the use of
bacterial artificial chromosome (BAC) technology. Such modified genomes have potential uses in
understanding viral pathogenesis, gene identification and characterization, and the development of
new viral vectors and vaccines. We have previously described the construction of a herpes simplex
virus 2 (HSV-2) BAC and the use of an allele replacement strategy to construct HSV-2
recombinants. While the BAC mutagenesis procedure is a powerful method to generate HSV-2
recombinants, particularly in the absence of selective marker in eukaryotic culture, the mutagenesis
procedure is still difficult and cumbersome.
Results: Here we describe the incorporation of a phage lambda recombination system into an
allele replacement vector. This strategy enables any DNA fragment containing the phage attL
recombination sites to be efficiently inserted into the attR sites of the allele replacement vector
using phage lambda clonase. We also describe how the incorporation of EGFP into the allele
replacement vector can facilitate the selection of the desired cross-over recombinant BACs when
the allele replacement reaction is a viral gene deletion. Finally, we incorporate the lambda phage
recombination sites directly into an HSV-2 BAC vector for direct recombination of gene cassettes
using the phage lambda clonase-driven recombination reaction.
Conclusion: Together, these improvements to the techniques of HSV BAC mutagenesis will
facilitate the construction of recombinant herpes simplex viruses and viral vectors.
Background
Complete viral genomes of large DNA viruses (e.g. herpes-
viruses) can be incorporated as bacterial artificial chromo-
somes (BACs). One method is the use of replicons based
on the bacterial F plasmid [1]. Since the initial report that
described the BAC cloning of a murine cytomegalovirus
genome [2], several additional herpesvirus genomes have
been cloned as BACs [3-14], including herpes simplex
virus 1 (HSV-1) and herpes simplex 2 (HSV-2) [15-18].
BAC technology created new possibilities for the targeted
mutagenesis of the herpesvirus genome (for recent
reviews, see [19,20]). Since the viral genome can be car-
ried as an episome in bacterial cells, prokaryotic genetic
techniques can be employed for manipulation of the viral
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genome without the need for typical selective mecha-
nisms required for mutagenesis and selection in eukaryo-
tic cells. This allows for the generation of viral mutants
that would be difficult to obtain otherwise, either because
of the lack of a phenotypic effect due to mutation or
because the mutation confers a disadvantage for selection
and replication in eukaryotic cells. Viral particles are
obtained by transfection of BAC-cloned viral DNA into a
permissive cell line. Since the mutant virus is clonally
derived, plaque purification of the recombinant virus is
usually not needed. In addition, the BAC and BAC-
derived virus can be easily shuttled back and forth
between E. coli and eukaryotic cells, facilitating analysis of
the effects of targeted mutation and subsequent sequen-
tial mutations. The power and versatility of BAC mutagen-
esis for studying herpesviruses has been used in numerous
ways, including studies on viral pathogenesis, the role of
viral antigens in immunity (for examples see [17,21]).
Modified viral genomes have potential uses in other areas
such as the construction and development of novel viral
vectors and vaccines.
Despite the power and the promise of BAC technology,
BAC mutagenesis can be difficult and cumbersome. While
the generation of a herpes virus BAC is similar in all
approaches through introduction of prokaryotic F-factor
plasmid features into the viral genome using homologous
recombination [2,4], different approaches to BAC muta-
genesis have been described. In our past studies, we used
the method published by Horsburgh and co-workers
[4,15] that uses a gene replacement vector that features a
temperature-sensitive origin of replication (ts-ori), a posi-
tive selection marker (zeocin) and negative selection
marker (sacB). Other methods to mutagenize herpes BACs
such as transposon mutagenesis [22] and PCR-based
approaches [23] are efficient and do not require the con-
struction of a special gene replacement vector for each
mutation. However, these techniques do not easily allow
the generation of certain types of manipulations such as
point mutations. BAC recombineering [24,25], a BAC
mutagenensis method which uses lambda-mediated
homologous recombination in Escherichia coli, can be
used to efficiently generate extensive mutations in any tar-
geted allele but is an in vivo system requiring special E. coli
strains and is a two step procedure that necessitates that
the targeted allele be substituted and then replaced with
the desired mutation.
The aim of the present study was to simplify BAC muta-
genesis, using approaches tailored to the final application.
We believe this method can be used for a broad range of
applications. Here we describe two examples how the
incorporation of a lambda phage recombination system
can greatly simplify the construction of allele replacement
vectors. In addition, we describe how EGFP can be utilized
for easy screening of positive clones throughout the proc-
ess of in vivo allele replacement in E. coli when the allele
replacement procedure is a gene deletion. Finally, we
describe the incorporation of the lambda phage recombi-
nation system directly into an HSV-2 BAC so that gene
transfer into a specific viral locus can be performed in a
simple one-step in vitro reaction. These improvements to
the techniques of HSV BAC mutagenesis will facilitate the
construction of recombinant herpes simplex virus
genomes.
Results and discussion
Construction of an improved allele replacement plasmid 
vector containing lambda phage site specific 
recombination sites
An allele replacement strategy for mutagenesis of bacterial
artificial chromosomes has been previously described [4].
This strategy utilizes plasmid replacement vector pKO5,
containing the elements for positive selection of the inte-
grated allele via a single cross-over event (a temperature-
sensitive origin of replication ts-ori, and a zeocin resist-
ance gene zeo), and an element for negative selection to
force recombination necessary for allele replacement
(sacB). A simplified version of the allele replacement strat-
egy is shown in Figure 1.
Plasmids such as pKO5 contain positive and negative
selection markers making it extremely powerful for BAC
mutagenesis. However, plasmids derived from pKO5 are
difficult cloning vectors to use because of the limited
number of restriction sites available for insertion and the
low frequency of recombinant transformants obtained
during the cloning procedure. As a means to address these
limitations we inserted an ~1.6 kb DNA fragment contain-
ing attR lambda phage recombination sites into pKO5. A
schematic drawing of the constructed vector pKO5.2-C.1
is shown in Figure 2. Phage lambda recombination is a
highly specific, directional, and conservative recombina-
tion reaction, mediated by the lambda clonase enzyme,
that occurs between two site-specific attachment sites (attL
and attR). In addition to the lambda recombination sites,
this gene cassette contains the ccdB gene [26] which is a
negative selection marker designed to minimize the
number of non-recombinant transformants obtained dur-
ing cloning. Thus, any DNA fragment containing attL
recombination sites can be efficiently inserted into the
attR sites in the pKO5.2-C.1 vector using phage lambda
clonase (designated as the LR recombination reaction),
and the resultant recombinant plasmids are ready for the
allele replacement reaction.
Use of EGFP to facilitate screening of BACs containing 
replaced alleles
As depicted in Figure 1, the allele replacement procedure
includes a single cross over event that results in the gener-BMC Biotechnology 2007, 7:22 http://www.biomedcentral.com/1472-6750/7/22
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ation of a BAC intermediate that contains two copies of
the targeted allele, one from the starting BAC and one
from the replacement vector. In theory, resolution of this
intermediate should have an equal chance of generating
the original BAC or a new BAC with the replaced allele. In
practice, we have not found this to be the case, with the
percentage of screened clones containing the replaced
allele as low as 5%, but always much lower than the
expected 50% (data not shown). For example, in a previ-
ously reported study, we constructed an allele replace-
ment vector using the improved vector pKO5.2-C.1 as
described above, and used BAC mutagenesis to generate
an HSV-2 genome that was deleted for the essential gene
encoding glycoprotein D [17]. While the construction of
the allele replacement vector containing the flanking
regions of the gD gene, but missing the coding sequences,
was relatively straight-forward, a large number of colonies
in the final step of the allele replacement procedure had
to be screened in order to find the desired BAC recom-
binant with the gD deletion. It is likely that the percentage
of replaced allele to starting allele containing BACs is at
least somewhat dependent upon the size of the flanking
sequences used in the allele replacement vector, but con-
struction of allele replacement vectors with exceptionally
large flanking sequences is not always practical. Conse-
quently, we reasoned that for allele replacement reactions
which are gene deletions, co-expression of EGFP in the
replacement vector would aid in the detection of the
desired cross-over recombinant BACs.
To evaluate the feasibility of EGFP co-detection for
obtaining the desired resolved BAC containing a targeted
gene deletion, we designed a new HSV-2 gD-deletion
replacement vector containing the EGFP gene in place of
the  gD  coding sequences and transferred this chimeric
gene to the BAC insertion shuttle vector pKO5.2-C.1 by
the LR recombination reaction, resulting in pKO5.2-C.1-
gD-EGFP (Figure 2). The gD flanks with the inserted EGFP
Construction of allele replacement vector pKO5.2-C.1-gD- EGFP using LR recombination Figure 2
Construction of allele replacement vector pKO5.2-
C.1-gD-EGFP using LR recombination. (A) Schematic 
diagram of the pKO5.2-C.1 plasmid vector containing the 
original KO5 selection markers, the lambda recombination 
sites (attR) and the negative selection marker for recombina-
tion (ccdB gene). (B) Schematic diagram of the plasmid 
pENTR-gD-EGFP containing attL recombination sites and the 
EGFP gene in place of the HSV-2 glycoprotein D gene. (C) 
Schematic diagram of the resulting allele insertion vector fol-
lowing in vitro recombination between pKO5.2-C.1 and 
pENTR-gD-EGFP. (D) Schematic diagram of the resulting 
plasmid by-product of the LR recombination reaction.
Schematic diagram of allele replacement strategy using vector  pKO5 Figure 1
Schematic diagram of allele replacement strategy 
using vector pKO5. (A) Features of a typical allele replace-
ment vector include a positive selection marker for antibiotic 
resistance marker (zeo), a temperature-sensitive origin of 
replication (ts-ori), a negative selection marker (sacB) and 
flanking sequences to targeting cross-over at hypothetical 
gene D. Incubation at non-permissive temperature (43°C) 
and selection on Zeocin/Chloramphenicol lead to co-integra-
tion through homologous recombination (single cross-over). 
(B) Diagram of the resultant single-crossover recombinant 
BAC and the two possible forms following resolution. Incu-
bation at permissive temperature (30°C) and selection on 
Zeocin/Sucrose lead to resolution of the co-integrate, exci-
sion of the plasmid through homologous recombination 
(double cross-over).BMC Biotechnology 2007, 7:22 http://www.biomedcentral.com/1472-6750/7/22
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were then transferred into the HSV-2 BAC by transforma-
tion of HSV2-BAC-containing RR1 electrocompetent cells
and selection of bacterial colonies on chloramphenicol/
zeocin (Cam/Zeo) plates at 30°C. Colonies at this stage
contained both the HSV2-BAC (choramphenicol marker)
and the allele insertion plasmid (zeocin marker) but not
necessarily a recombinant BAC because both the BAC and
the plasmid will replicate at this temperature. The follow-
ing day, multiple colonies were picked into 1 ml of LB
broth and plated in serial dilutions onto Cam/Zeo plates
at 43°C, conditions that require integration of the inser-
tion plasmid into the HSV2-BAC vector. Individual colo-
nies from the 43°C plate were re-plated onto sucrose/
chloramphenicol (Suc/Cam) plates at 30°C to force reso-
lution of the single cross-over co-integrate. Six colonies,
selected from each of 14 original 43°C colonies, were
then transferred to chloramphenicol plates at 30°C and
visualized for EGFP expression (Figure 3A). Five of the 14
colonies we selected as a representative sample expressed
the EGFP indicator gene, and were shown by PCR analysis
to contain the EGFP gene replacing the gD gene (data not
shown). In addition, as previously described [17], virus
derived from the gD-deleted/EGFP-inserted HSV2-BAC
was unable to grow on Vero cells following transfection,
whereas viable virus was recovered following transfection
of VD60 cells (Vero-derived cells expressing glycoprotein
D). Eukaryotic cells infected with the resulting recom-
binant virus did not express EGFP, consistent with the fact
that the inserted EGFP gene is under control of a prokary-
otic promoter. A schematic diagram of the BAC-derived
HSV-2 genome containing EGFP inserted into the gD gene
is shown in Figure 3B. Thus, expression of EGFP is a suit-
able choice for screening of the BAC recombinant con-
taining insertions, especially when the percentage of allele
replaced BACs is relatively low.
Use of lambda phage site specific recombination sites in an 
HSV-2 BAC vector for direct recombination of gene 
cassettes using the LR recombination reaction
Although both procedures described above simplify cer-
tain aspects of the allele replacement reaction, the process
still requires the construction of a plasmid replacement
vector and is a multi-step selection procedure. Conse-
quently, we were interested in determining whether gene
replacements could be performed directly in the BAC
using the efficient lambda phage recombination system.
We chose the UL41 gene for insertion of attR recombina-
tion sites into the HSV2-BAC since it is known that the
UL41 gene encodes the virion host shutoff (vhs) protein
that is dispensable for virus replication in cell culture.
Toward this end, an insertion plasmid was constructed
that contained ~4 kb of DNA sequences surrounding the
UL41 gene. In place of the UL41 ORF, we inserted the gene
encoding EGFP under control of a prokaryotic promoter
flanked by the attR recombination sites. A schematic dia-
gram of the pKO5.2-UL41 attR-EGFP is shown in Figure
4A. This insertion vector also contained the previously
described selection markers, the attR recombination sites,
and the EGFP gene. Screening of the recombinant HSV-
BAC containing attR-EGFP in UL41 was aided by expres-
sion of the EGFP in bacterial colonies and insertion was
confirmed by PCR analysis using primer pairs in the EGFP
gene and the flanking UL41 sequences (data not shown).
The resulting HSV-BAC, designated as DEST-BAC (Figure
4B), was isolated to study its suitability as an in vitro des-
tination vector for DNA fragments flanked by attL
sequences. This BAC DNA was infectious when trans-
fected into Vero cells (data not shown).
Unlike the allele plasmid replacement vectors containing
attR recombination sites (Figure 2A), the DEST-BAC does
not contain a negative selection marker such as the ccdB
gene. Thus, following an in vitro recombination reaction
with DEST-BAC and a fragment containing the attL sites,
there is no suppression of the growth of bacterial trans-
Construction of HSV2-BAC ∆gD Figure 3
Construction of HSV2-BAC ∆gD. (A) Visualization of 
EGFP-containing BAC colonies after transformation follow-
ing the allele replacement procedure. Bacterial clones har-
boring mutant (∆gD) HSV2-BAC glow green because of 
insertion of EGFP at the site of US6. (B) Schematic diagram of 
HSV2-BAC with EGFP insertion at US6(gD). pBeloBAC11 
refers to the insertion of the BAC sequences into UL23 (tk) 
of the viral genome.BMC Biotechnology 2007, 7:22 http://www.biomedcentral.com/1472-6750/7/22
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formants harboring either the original HSV-BAC and/or
the plasmid by-products of the LR reaction (Figure 5).
Nevertheless, DEST-BAC contains the EGFP gene which is
expressed in prokaryotic cells and thus screening of
recombinant BACs into which insertion has occurred
should be facilitated by loss of this marker. In order to
evaluate direct recombination into DEST-BAC via the in
vitro recombination reaction, we constructed several vec-
tors, each containing a different DNA fragment between
attL recombination sites (Figure 6A). One of the plasmid
vectors contained the gene encoding DsRed2 under con-
trol of a prokaryotic promoter to allow visualization of
the various BAC recombinants that might be generated
following the recombination reaction. The other two vec-
tors contained the genes encoding the vaccinia virus A33R
and B5R glycoproteins under control of eukaryotic pro-
moters to determine the ability of inserted genes to be
expressed in the recombinant BAC viruses. The A33R and
B5R genes were each fused to an epitope tag from the
influenza hemagglutinin gene for easy identification of
the expressed gene product.
Recombination between the high copy number pDsRed2
vector and the low copy number GFP-expressing DEST-
BAC was carried out in the standard in vitro reaction, fol-
lowed by transformation of electrocompetent E. coli
DH10B and plating onto LB plates containing either
Chloramphenicol or Kanamycin. Transformants arising
on Cam plates derived from the reaction with pDsRed2
(Figure 6A) showed four distinct phenotypes, bright red
(I), weak green (II), bright green (III), and not glowing/
weakly red (IV) (Figure 6B). The majority (54 of 92) of
transformants were of the not glowing/weakly red (IV)
phenotype (numbers on the right in Fig. 6B). These colo-
nies were able to grow in the presence of chlorampheni-
col, but not kanamycin, suggesting the presence of the
recombinant DsRed2-inserted BAC. Transformants of the
weak green (II) phenotype were also able to grow in the
presence of chloramphenicol but not kanamycin, suggest-
ing the presence of the starting EGFP-expressing BAC. In
contrast, the bright red colonies (row I) and the bright
green colonies (row III) were also able to grow on LB Kan
plates (data not shown), suggesting that these types of col-
onies contained a kanamycin resistant plasmid (either the
plasmid by-product of the in vitro recombination reaction
or the original vector) in addition to a chloramphenicol-
resistant BAC. Further studies demonstrated that by reduc-
ing the concentration of DNA used for transformation,
the number of such double transformants could be
reduced and also result in higher overall transformation
efficiency (data not shown).
The color and antibiotic sensitivity results suggested that
the desired HSV BAC containing the DsRed2 insert would
be contained in colonies with the not glowing/weakly
emitting red phenotype due to the fact that the DsRed2
indicator gene product is only barely visible in colonies.
Outline of the recombination reaction between DsRed2  allele replacement vector and DEST-BAC Figure 5
Outline of the recombination reaction between 
DsRed2 allele replacement vector and DEST-BAC. 
Products of the forward reaction are the recombinant BAC 
(DsRed2-BAC) and a plasmid by-product (pEGFPbp).
Construction of an HSV-2 BAC containing attR lambda  recombination sites Figure 4
Construction of an HSV-2 BAC containing attR 
lambda recombination sites. (A) Schematic diagram of 
allele replacement vector pKO5.2-UL41-attR-EGFP contain-
ing UL41 sequences flanking the attR sites on either side of 
the EGFP gene cassette. (B) Schematic diagram of DEST-BAC, 
and HSV2-BAC containing the EGFP gene flanked by lambda 
phage attR sites for targeting gene replacements into UL41.BMC Biotechnology 2007, 7:22 http://www.biomedcentral.com/1472-6750/7/22
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This phenotype, compared to the brighter green appear-
ance of colonies expressing EGFP protein, is presumably
because of the low BAC copy number and the slower mat-
uration of the functional tetrameric DsRed2 protein com-
pared to the monomeric EGFP protein. To determine
whether the weakly emitting red colonies contained the
desired HSV BAC, individual colonies of this phenotype
were analyzed by PCR using primer sets specific for
DsRed2, the UL41 flanking sequences, EGFP, and 3 HSV-2
genes well separated on the HSV-2 genome (UL2, UL45,
and US12). Figure 7A (left panel) shows the DsRed2 PCR
results for 4 of the colonies. The presence of the 424 bp
product from the PCR using the DsRed2 primer set indi-
cates that each colony contained the DsRed2 gene. These
same colonies were negative for EGFP by PCR using the
primer set specific for that gene (bottom half of Figure
7B). In addition, the PCR using the UL41 primer set gen-
erated the expected 1290 bp product consistent with elim-
ination of the 970 bp containing the EGFP gene from
DEST-BAC and insertion of the 940 bp containing the
DsRed2 gene (top half of Figure 7B). Finally, the presence
of HSV-2 viral sequences in each clone was confirmed
with the PCR using the HSV-2 primer sets (data not
shown). Together, these results indicated that the pale
glowing/weakly emitting red colonies contained the HSV
BAC with the inserted DsRed2 gene. The recombinant BAC
DNA was infectious as shown by formation of virus after
transfection of the BAC DNA from 2 independent clones
into Vero cells (data not shown). An additional 12 colo-
nies, selected from the plate on the basis of weakly emit-
ting red phenotype were analyzed in the same manner,
and the results were identical to those of the first 4 colo-
nies shown in Figure 7 (data not shown). Therefore, direct
recombination into the HSV-BAC template is feasible for
BAC insertion mutagenesis, and that the lack of a negative
selection (e.g., ccdB gene) was not critical for the selection
procedure. Since colonies without color yielded the
desired HSV BAC, these results suggest that this technique
would be applicable for the insertion of any fragment
flanked by attL recombination sites, particularly if the
starting BAC template expressed an EGFP gene.
PCR Analysis of HSV-2 BAC recombinants Figure 7
PCR Analysis of HSV-2 BAC recombinants. (A) Insert-
specific PCR of 4 individual clones each of HSV2-BAC 
recombinants containing an inserted DsRed2 (left panel), vac-
cinia virus B5R (middle panel) or vaccinia virus A33R gene 
(right panel). Lane M -100 bp molecular size markers. Lane P 
– Specific plasmid controls containing the genes for DsRed2, 
B5R, A33R, respectively (from left to right). Sizes of PCR 
products are: DsRed2 – 424 bp; B5R – 1014 bp; A33R – 586 
bp. (B) UL41 and EGFP PCR analysis of 4 individual clones 
each of HSV2-BAC recombinants containing an inserted vac-
cinia virus B5R (lanes 1–4), vaccinia virus A33R gene (lanes 5–
7), or DsRed2 gene (lanes 9–12). Lane M -100 bp molecular 
size markers. Lane 13 – HSV2-BAC. Lane 14 – DEST-BAC. 
The top half of the gel shows the PCR products generated 
with UL41 primers for each clone. Sizes of UL41 PCR prod-
ucts are: B5R – 2280 bp; A33R – 1850 bp; DsRed2 – 1290 bp 
(DsRed2); HSV2-BAC – 342 bp; UL41 PCR of DEST-BAC – 
1320 bp). The bottom half of the gel shows the PCR prod-
ucts using EGFP primers for each clone, confirming the 
absence of the EGFP in each recombinant. Size of EGFP PCR 
product of DEST-BAC is 433 bp (lane 14).
In vitro recombination of allele replacement vectors into  DEST-BAC, transformation, and visualization of resultant  phenotypes Figure 6
In vitro recombination of allele replacement vectors 
into DEST-BAC, transformation, and visualization of 
resultant phenotypes. (A) Schematic diagram of allele 
replacement vectors featuring DsRed2, A33R, and B5R. (B) 
Four visual phenotypes of colony transformants observed 
after in vitro recombination between DEST-BAC and 
pDsRed2 and transformation. Colony transformants from a 
typical transformation were replated onto a chlorampheni-
col-containing agar plate to demonstrate phenotype differ-
ences. Numbers to the right of the plate refer to the actual 
numbers of each colony phenotype observed on the original 
transformation plate.BMC Biotechnology 2007, 7:22 http://www.biomedcentral.com/1472-6750/7/22
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Similarly, we investigated the feasibility of direct in vitro
recombination into DEST-BAC using the attL flanking
B5R and A33R gene constructions (schematic diagrams
shown in Figure 6A). Since there was no marker gene for
visualization of the desired recombinant BAC, transform-
ants showed only three phenotypes on LB Cam plates,
bright green, slightly green, and non-glowing. As in the
DsRed2 example, very bright green colonies were viable
on LB Kan plates suggesting the presence of an EGFP-con-
taining plasmid by-product in addition to a BAC. Since
slightly green colonies growing on chloramphenicol sug-
gested the presence of the starting BAC template, we ana-
lyzed colonies without color and that were unable to grow
on LB Kan plates for the presence of the desired B5R or
A33R BAC recombinant. Four clones each from the B5R
and A33R recombination reaction/transformation were
screened for the presence of the transgene by PCR using
sequence-specific primers for B5R or A33R (Figure 7A).
Each colony without color from the B5R reaction had the
expected 1014 bp B5R PCR product (Figure 7A, middle
panel) and each colony without color from the A33R reac-
tion had the expected 586 bp A33R PCR product (Figure
7A, right panel). Absence of a PCR DNA fragment when
using EGFP primers confirmed the loss of the EGFP gene
in all of these colonies (bottom half of Figure 7B). In addi-
tion, the PCR using the UL41 primer set revealed the
expected sizes at the UL41 locus for both the B5R and
A33R recombinant HSV-BACs, 2280 bp and 1850 bp,
respectively (top half of Figure 7B).
To determine whether the recombinant A33R- and B5R-
containing HSV BACs expressed the inserted proteins
from the UL41  locus, Western blot analysis was per-
formed. Infectious virus derived from BAC-transfected
Vero cells was used to prepare a virus stock for subsequent
infection experiments. Lysates from infected Vero cells
were harvested and the proteins separated on a polyacry-
lamide gel and transferred to nitrocellulose membranes
for immunoblotting with a monoclonal antibody against
the HA epitope tag that is present on both recombinant
proteins (Figure 8). In each case, an expressed protein of
the predicted size was apparent.
Recombinant viruses isolated through the BAC mutagen-
esis procedure should be clonal, thus eliminating the need
for further plaque purification following transfection of
the BAC DNA into eukaryotic cells. To confirm this, we
infected Vero cell cultures with the A33R- and B5R-
expressing recombinant viruses obtained from the BAC
insertion procedure. After plaques started to appear, cell
monolayers were fixed and probed with the mouse anti-
HA monoclonal antibody (Figure 9). In plates containing
hundreds of virus plaques, every plaque was stained by
the monoclonal to the epitope tag, indicating both the
Immunostained viral plaques of recombinant viruses derived  by the BAC allele replacement technique Figure 9
Immunostained viral plaques of recombinant viruses 
derived by the BAC allele replacement technique. 
Virus was isolated following transfection of Vero cells with 
recombinant HSV2-BACs expressing A33R or B5R, titered 
and used to infect plates of Vero cells. Monolayers were 
fixed and then probed with mouse anti-HA monoclonal anti-
body, followed by AP-conjugated goat anti-mouse antibody. 
(A) B5R-expressing HSV2-BAC virus infected cells. (B) 
A33R-expressing HSV2-BAC virus infected cells.
Expression of transgenes from recombinant HSV-2 BACs Figure 8
Expression of transgenes from recombinant HSV-2 
BACs. Vero cells were infected with either A33R-expressing 
(Lanes 1–2) or B5R-expressing (Lanes 4–5) HSV2-BAC 
recombinant viruses. Infected cells were harvested and ana-
lyzed by Western blot using mouse anti-HA monoclonal anti-
body. Detection was done with an HRP-conjugated sheep 
anti-mouse antibody. The blot was visualized by chemilumi-
nescence. Lane 3 – Molecular size markers (kDa).BMC Biotechnology 2007, 7:22 http://www.biomedcentral.com/1472-6750/7/22
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clonal nature of the virus derived by BAC mutagenesis as
well as the stability of the derived recombinant viruses.
We have shown that any DNA fragment flanked by attL
recombination sites can be inserted directly into DEST-
BAC or any other HSV BAC containing attR sites. This pro-
cedure is feasible even without a negative selection marker
such as the ccdB gene. While there is no selective pressure
against bacterial colonies harboring the original DEST-
BAC, the majority of colony transformants obtained har-
bor the desired recombinant BAC (Fig. 6B). This is likely
due to the molar ratio of attR sites to attL sites in the in
vitro  recombination reaction. Since the attR-containing
BAC is approximately 50 times as large as the attL-contain-
ing replacement vector, there will be a limiting number of
attR sites and the in vitro recombination reaction will be
driven towards insertion of the fragment from the allele
replacement plasmid into the BAC.
Somewhat similar recombinase systems have recently
been reported that describe the construction of recom-
binant herpesvirus BACs with inserts into ICP6 rather
than UL41 [27,28]. In these systems, the Cre/lox recombi-
nase system was used to insert a transgene into the ICP6
gene of HSV, the same site that was engineered to harbor
the BAC replication sequences. A second recombination
system (FLPe/FRT) was used during transfection of mam-
malian cells to eliminate the BAC sequences. The desired
recombinant, missing the BAC sequence but with the
desired insert at the ICP6 locus, was then plaque purified.
These systems have the advantage of being able to yield a
recombinant virus with an inserted transgene without
remaining prokaryotic BAC sequences. The procedure
however, requiring more manipulations than the DEST-
BAC procedure and plaque purification of the final virus
product, is relatively lengthy. Thus, each system has its
advantages, and the most appropriate system to be used
for construction of a recombinant herpes virus using a
BAC system will depend upon the desired characteristics
of the recombinant virus that is being constructed.
Conclusion
In summary, BAC technology is an extremely powerful
method for construction of complex recombinant herpes
simplex viruses, particularly in instances when there is no
selective mechanism for the desired recombinant. The
improvements to the allele replacement procedure
described in this report facilitate both complex and rou-
tine constructions. For any type of allele replacement,
cloning into pKO5-derived vectors is greatly simplified by
use of the lambda recombination system. The clonase
enzymes are commercially available and provide high lot-
to-lot consistency for reliable results. In addition, there
are a large number of vectors available that incorporate
the attL recombination sites making it easy to integrate
BAC mutagenesis with projects involving expression stud-
ies of target proteins in different expression systems. For
allele replacements which are gene deletions, selection of
bacterial colonies containing the desired BAC-deletion
mutant is aided by the use of EGFP visualization. Finally,
construction of series of viruses or vectors containing
mutations or insertions into a single locus of the viral
genome can be expedited by construction of a recipient
BAC containing the lambda recombination sites followed
by direct recombination into the HSV-BAC. Taken
together, these techniques provide improved methods for
the construction of recombinant herpes simplex viruses
and virus vectors.
Methods
Construction of plasmids and BACs
Platinum Pfx DNA polymerase (Invitrogen, Carlsbad, CA)
was used for PCR reactions to amplify DNA sequences for
subsequent cloning. Takara ExTaq polymerase (Takara,
New York, NY) was used for all analytical PCR. The
authenticity of all constructs throughout this study was
confirmed by sequencing using the BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA). Plasmid DNA was isolated using Qiawell or
Qiaprep Plasmid prep (Qiagen Inc., Valencia, CA). Elec-
trocompetent RR1 cells were prepared using ice-cold
water and 10% glycerol essentially as described in [29].
BAC DNA was isolated from a large culture (1.5 liters)
using Qiagen's Large-Construct kit. Routine molecular
biology procedures used in the course of plasmid con-
structions and characterization were based on those
described in [29]. Restriction enzymes, calf intestinal
phosphatase (CIP), and Klenow fragment used to blunt
DNA fragments were obtained from NEB (Beverly, MA).
Antibiotics and supplements in solid agar plates and liq-
uid media were used at the following concentrations:
zeocin (Zeo), 25 µg/ml; kanamycin (Kan), 50 µg/ml;
chloramphenicol (Cam), 20 µg/ml; Ampicillin (Amp),
100 µg/ml; Sucrose (Suc) 5% (w/v).
pKO5.2-C.1
Vector pKO5.2-C.1 is a derivative of pKO5, modified for
use as a destination vector by the insertion of a gene cas-
sette containing attR recombination sites into the multi-
ple cloning region. To achieve that, pKO5 was digested
with SalI and NotI and treated with calf intestinal phos-
phatase (CIP). Reading frame cassette C.1 (Gateway vec-
tor conversion system, Invitrogen) was ligated with the
linearized pKO5 and transformed into E. coli DB3.1 cells
(Invitrogen). DB3.1 cells are resistant to the effects of the
product of ccdB gene located between the attR flanks of
C.1 reading frame in pKO5.2-C.1.BMC Biotechnology 2007, 7:22 http://www.biomedcentral.com/1472-6750/7/22
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pENTR-gD-EGFP
This vector is based on a previously described plasmid
pENTR-1A-gD5678 [17]. To construct pENTR-gD-EGFP,
pEGFP (Clontech, Mountain View, CA) was digested with
PvuII and StuI to obtain an ~1 kb fragment harboring the
gene coding for the Enhanced Green Fluorescent Protein
(EGFP) downstream of a prokaryotic (Plac) promoter. The
fragment was cloned into a KpnI-digested, Klenow-
blunted pENTR-1A-gD5678, to obtain pENTR-gD-EGFP.
The gD flanks with the inserted EGFP were transferred by
LR recombination to the BAC insertion shuttle vector
pKO5.2-C.1, to generate pKO5.2-C.1-gD-EGFP.
DEST-BAC
To construct the UL41-insertion vector, two regions of the
HSV-2 (Genbank accession number NC_001798) UL40-
UL42 region were amplified by PCR using the following
primers:
UL41_BglII (5'GCGAGATCTGTATGTCACAGAGAAG-
GCGGACGGG)
UL41_EcoRI (5'GCGGAATTCTGGCCCAACAGATCGCG-
GGCGAGG)
UL41_HindIII (5'GCGAAGCTTGAAGTACTGCAGCAG-
GTCGCGGCAG)
UL41_XhoI (5'GCGCTCGAGAATGTGCGGTGTGTGTTT-
TCCCCG)
The resulting BglII-EcoRI and HindIII-XhoI fragments con-
taining approximately 2 kb downstream and upstream
flanking sequences of the UL41 gene, respectively, were
cloned into pSP72 (Promega, Madison, WI) to generate
pUL41. pUL41 was digested with enzymes HindIII and
EcoRI and treated with Klenow. Reading frame cassette A
(Gateway vector conversion system, Invitrogen) was
ligated into the linearized vector, giving rise to plasmid
vector pUL41-attR-ccdB-cat. The plasmid was maintained
in E. coli DB3.1 cells.
Plasmid pUL41-attR-ccdB-cat was digested with SalI,
treated with Klenow, and was partially digested with NotI.
The product was ligated with a PvuII/NotI fragment from
plasmid pEGFP, containing the EGFP gene with a prokary-
otic promoter (Plac). The resulting construct, pUL41-attR-
EGFP, was digested with BglII/XhoI. A fragment contain-
ing the UL41 flanks with attR sequences and EGFP was
transferred to BglII/XhoI digested pKO5.2, to obtain
pKO5.2-UL41-attR-EGFP, the shuttle vector for allele
replacement into UL41 locus of HSV2-BAC. DEST-BAC
was generated from HSV2-BAC by allele replacement of
the HSV2-BAC UL41 gene with the disrupted UL41 gene
containing the attR flanks and EGFP. Successful allele
replacement was detected visually by expression of EGFP,
and confirmed by PCR analysis, using three sets of HSV2-
specific primer pairs, UL41 primers flanking the insertion
site, and primers amplifying a product within EGFP gene.
The resulting recombinant BAC DNA was transfected into
Vero cells. Presence of plaques on a Vero cell monolayer
confirmed that the recombinant BAC is infectious.
DsRed2, A33R, and B5R allele replacement vectors
A set of allele replacement vectors were designed to study
aspects of the LR recombination reaction and to investi-
gate transfer of a suitable transgene to a viral BAC. These
vectors are based on pENTR-1A (Invitrogen) and con-
tained either DsRed2 or the vaccinia virus A33R or B5R
genes. To insert the DsRed2 gene, pENTR-1A was digested
with SalI/NotI, followed by treatment with Klenow to fill
in overhangs, and ligation of the PvuII/StuI fragment con-
taining DsRed2  and the lac  promoter (pDsRed2, Clon-
tech). To insert the B5R gene, plasmid pDNA3-B5R-HA
(Clement Meseda, manuscript in preparation) was
digested with restriction enzymes BglII (blunted with Kle-
now) and PvuII to obtain an expression cassette of vac-
cinia virus B5R gene fused to an HA-tag under the control
of the CMV promoter. The fragment was than cloned into
the blunted, SalI/NotI digested pENTR-1A vector. Simi-
larly, the plasmid pcDNA3-A33R-HA (Clement Meseda,
manuscript in preparation) was digested with restriction
enzymes NruI and PvuII, to obtain an expression cassette
of the A33R gene with an HA-tag under the control of the
CMV promoter, and ligated with SalI/NotI digested, Kle-
now-treated pENTR-1A vector. Transformed E. coli har-
boring entry vectors were grown on LB Kan medium.
In vitro LR recombination
LR recombination reactions were performed using the
Gateway LR Clonase enzyme mix (Invitrogen) as
described in the manufacturer's protocol. Modifications
are described. Briefly, the enzyme mix contains the bacte-
riophage lambda recombination proteins Integrase (Int)
and Excisionase (Xis), and the E. coli-encoded protein
Integration Host Factor (IHF). Each reaction was per-
formed in a 20 µl volume, using 150 ng of DEST-BAC
DNA and 100 ng of entry vector DNA. Reactions were
incubated overnight at room temperature. After Protein-
ase K treatment, ten-fold and 100-fold dilutions were
transformed into electrocompetent DH10B cells (Invitro-
gen). The electroporation conditions employed 0.1 cm
cuvets and 1.7 kV/25 µF/200  Ω settings on a BioRad
GenePulser II. Clones were confirmed by PCR with primer
pairs targeting sequences in the inserted genes (DsRed2,
A33R, B5R), and with HSV-2 UL41-specific primers
(UL_41_F; 5'GGGGGTCTTCTTCGTAGTCG and
UL_41_R; 5'ACATCAGCACCGGCTACATT) hybridizing
close to the site of insertion whereby generating fragments
of different size according to the inserted gene. A primerBMC Biotechnology 2007, 7:22 http://www.biomedcentral.com/1472-6750/7/22
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pair that amplifies a fragment in the EGFP gene was used
to show loss of EGFP in recombinant clones.
BAC mutagenesis
Mutagenesis of HSV2-BAC was performed as described
previously, employing a BAC replacement vector contain-
ing a temperature-sensitive origin of replication and
marker genes for positive and negative selection during
the BAC mutagenesis procedure [4,15]. Briefly, electro-
competent RR1 E. coli cells were transformed with HSV2-
BAC DNA and selected for chloramphenicol resistance.
The electroporation conditions employed 0.1 cm cuvets
and 1.7 kV/25 µF/200 Ω settings on a BioRad GenePulser
II. Clones were confirmed by PCR with 3 independent
HSV-2 specific primer pairs and a primer pair that ampli-
fies a fragment in the chloramphenicol acetyltransferase
(cat) gene. A 620 bp fragment in the cat gene was ampli-
fied with the following primers: MM507 (5'GCCCAT-
GGTGAAAACGGGGGC) and MM508
(5'GATCGGCACGTAAGAGGTTCC).
Electrocompetent RR1 cells harboring the HSV2-BAC
were prepared as previously described [29], and were elec-
troporated with 10 ng of the respective pKO5.2-derived
shuttle vector (pKO5.2-C.1-gD-EGFP or pKO5.2-UL41
attR-EGFP), and plated onto chloramphenicol/zeocin
(Cam/Zeo) plates in serial dilutions at 30°C. The follow-
ing day, multiple colonies were picked into 1 ml of LB
broth and plated in serial dilutions onto Cam/Zeo plates
and incubated at 43°C. Colonies at 43°C were analyzed
by picking several into 1 ml LB each and plating out 20 µl
onto sucrose/chloramphenicol (Suc/Cam) plates at 30°C.
Approximately 10 colonies from each plate, representing
an original 43°C colony, were transferred to grids on Suc/
Zeo and Cam LB plates at 30°C. Colonies that were
Cam+, Zeo/Suc- were picked into 100 µl of 10 mM Tris pH
8.0 for colony PCR using HSV-2 specific primers. along
with either a primer pair flanking the UL41 coding region
(for insertion of the attR-EGFP cassette) or a primer pair
flanking the gD coding region (for insertion of EGFP to
delete  US6). Positive colonies were streaked on Cam
plates and grown at 37°C. Large scale BAC vector DNA
isolation was performed using the Large Construct kit
(Qiagen Inc., Valencia, CA).
Cells and viruses
Vero cells were obtained from the American Type Culture
Collection (ATCC, Manassas, VA) and maintained in Dul-
becco's Minimal Essential Medium (DMEM) supple-
mented with 10% fetal bovine serum, FBS (HyClone,
Logan, UT); 2 mM Glutamax-1; and 0.05 mg/ml Gen-
tamicin (Gibco/Invitrogen, Grand Island, NY). VD60
cells, a Vero cell line that expresses the HSV-1 gD [30],
were a gift from Dr. David C. Johnson, Department of
Molecular Microbiology & Immunology, Oregon Health
Sciences University. VD60 cells were maintained as sug-
gested in Eagle MEM lacking histidine (MEM-his) supple-
mented with 1 mM histidinol (Sigma Chemical Co., St.
Louis, MO) and 5% FBS. Prior to infection, VD60 cells
were passaged two times in DMEM containing 10% FBS.
Cells were seeded in 6-well plates at 8 × 105/well one day
before infection or transfection. The HSV-2 (MS) BAC
used as the parental clone for subsequent recombinant
BACs described in this study has been described previ-
ously [17].
Transfection of BAC DNA
Vero cells were transfected using Lipofectamine (Invitro-
gen, Carlsbad, CA), at a ratio of five µl per µg of plasmid
or BAC DNA. At 5 h after transfection, an equal volume of
complete media was added; media was changed again the
next day. Infected cell lysates were harvested and used to
infect Vero cells seeded at 2 × 106/flask in 25 cm2 tissue
culture vessels.
Infection of cells
For Western blot, cells were infected at a multiplicity of
infection (moi) of 5; for immunostaining, virus stocks
were titered to get a sufficient number of separated
plaques per well. Virus was added to the cell sheet in
about 1 ml of complete media per well. Plates were incu-
bated at 37°C for 2 hours, with gentle mixing of the
media by shaking the plate every 15 minutes. After that,
cells were overlaid with complete media (Western blot) or
methylcellulose (immunostaining).
Immunostaining of plaques
Infected cell sheets were fixed using a 1:1 mixture of meth-
anol/acetone. All wash steps were performed using Tris
buffered saline (TBS) with 0.1% Triton-X. Fetal bovine
serum at a concentration of 20% in TBS was used for
blocking. Mouse anti-HA monoclonal antibody was used
as primary antibody (diluted 1:1000). Detection was per-
formed with goat anti-mouse polyclonal antibodies con-
jugated to alkaline phosphatase (Promega, Madison, WI)
in combination with Western Blue stabilized substrate for
alkaline phosphatase (Promega). Pictures were taken with
a Canon G3 digital camera equipped with a HOYA +4
macro lens.
Western blot
Two days after infection, infected cells were harvested and
resuspended in lysis Buffer (50 mM Tris Cl pH 7.5; 150
mM NaCl; 1% Triton X-100) with EDTA-free Protease
Inhibitor Cocktail Tablets (Roche, Mannheim, Germany).
Proteins were fractionated on precast NuPAGE 12% Bis-
Tris gels (Invitrogen, Carlsbad, CA) and transferred elec-
trophoretically onto PVDF membrane (Bio-Rad Laborato-
ries, Hercules, CA) for subsequent Western blot. Mouse
anti-HA monoclonal antibody (Covance, Richmond, CA)BMC Biotechnology 2007, 7:22 http://www.biomedcentral.com/1472-6750/7/22
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at a dilution of 1:1000 was used to detect HA-tagged A33R
and B5R. Protein bands were detected by chemilumines-
cence, using horseradish peroxidase conjugated sheep
anti-mouse antibody (Amersham Biosciences, Piscataway,
NJ) at a dilution of 1:30000, and SuperSignal West Dura
detection reagents (Pierce, Rockford, IL). Digital pictures
were captured with a Fuji LAS-3000 CCD camera and soft-
ware supplied by the manufacturer.
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